| Item Type | Name |
|
Concept
|
Aged, 80 and over
|
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
|
Academic Article
|
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
|
|
Academic Article
|
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
|
|
Academic Article
|
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
|
|
Academic Article
|
Is patient travel distance associated with survival on phase II clinical trials in oncology?
|
|
Academic Article
|
Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients.
|
|
Academic Article
|
A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
|
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
|
Academic Article
|
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
|
|
Academic Article
|
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
|
|
Academic Article
|
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers.
|
|
Academic Article
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
|
Academic Article
|
A Phase II study of oxaliplatin in urothelial cancer.
|
|
Academic Article
|
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
|
|
Academic Article
|
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
|
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
|
|
Academic Article
|
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
|
|
Academic Article
|
Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer.
|
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
|
Academic Article
|
Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
|
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
|
Academic Article
|
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
|
|
Academic Article
|
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
|
|
Academic Article
|
Ethnic differences and functional analysis of MET mutations in lung cancer.
|
|
Academic Article
|
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.
|
|
Academic Article
|
Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.
|
|
Academic Article
|
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
|
|
Academic Article
|
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
|
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
|
Academic Article
|
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Chemoradiation for patients with large-volume laryngeal cancers.
|
|
Academic Article
|
Free-flap reconstruction in the doubly irradiated patient population.
|
|
Academic Article
|
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
|
|
Academic Article
|
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
|
|
Academic Article
|
Predictors of competing mortality in advanced head and neck cancer.
|
|
Academic Article
|
MET and phosphorylated MET as potential biomarkers in lung cancer.
|
|
Academic Article
|
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).
|
|
Academic Article
|
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
|
|
Academic Article
|
The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report.
|
|
Academic Article
|
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
|
|
Academic Article
|
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
|
|
Academic Article
|
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
|
|
Academic Article
|
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
|
|
Academic Article
|
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
|
|
Academic Article
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
|
Academic Article
|
Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.
|
|
Academic Article
|
Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.
|
|
Academic Article
|
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
|
|
Academic Article
|
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
|
|
Academic Article
|
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
|
|
Academic Article
|
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
|
|
Academic Article
|
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
|
|
Academic Article
|
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
|
|
Academic Article
|
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
|
|
Academic Article
|
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
|
|
Academic Article
|
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
|
|
Academic Article
|
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
|
|
Academic Article
|
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.
|
|
Academic Article
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
|
Academic Article
|
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
|
|
Academic Article
|
Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.
|
|
Academic Article
|
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.
|
|
Academic Article
|
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
|
|
Academic Article
|
Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
|
|
Academic Article
|
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
|
|
Academic Article
|
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
|
|
Academic Article
|
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
|
|
Academic Article
|
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
|
|
Academic Article
|
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.
|
|
Academic Article
|
The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC.
|
|
Academic Article
|
A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
|
|
Academic Article
|
Clinical prognostic model for older patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
|
|
Academic Article
|
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
|
|
Academic Article
|
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
|
|
Academic Article
|
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
|
|
Academic Article
|
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
|
|
Academic Article
|
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
|
|
Academic Article
|
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
|
|
Academic Article
|
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.
|